Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
Evaluate the safety and outcomes associated between the two treatment modalities
Assess the risk of vancomycin-associated nephrotoxicity and outcomes associated with
 continuous infusions (CI) versus II dosing in the outpatient parenteral antibiotic therapy
 (OPAT) setting
Inclusion Criteria:

 -  Adult patients at least 18 years of age

 -  Receiving Wake Forest Baptist Health OPAT services

 -  Will receive vancomycin therapy from Wake Forest Baptist Health Specialty Home
 Infusion Pharmacy

 -  Planned therapy with vancomycin in the outpatient setting for at least 2 weeks in
 duration

 -  Prescribed vancomycin with a frequency of either every 12 hours or every 8 hours
 dosing at the time of enrollment

 Exclusion Criteria:

 -  Presence of diseases or conditions known to affect the pharmacokinetics of vancomycin:

 Pregnancy/Ascites/Burn injury/Cystic fibrosis /Weight greater-than or equal-to 150 kg

 -  Pre-existing leukopenia:

 WBC < 4,000 x 103 cells/µL